Safety of ethyl acrylate to be used as flavouring

EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), Vittorio Silano, Claudia Bolognesi, Laurence Castle, Kevin Chipman, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Roland Franz, Konrad Grob, Rainer Gürttler, Trine Husøy, Sirpa Kärenlampi, Maria Rosaria Milana, Karla Paff, Gilles Riviere, Jannavi Srinivasan, Maria de Fátima Tavares Poças, Christina Tlustos, Detlef Wölfle, Holger Zorn, Romualdo Benigni, Mona-Lise Binderup, Leon Brimer, Francesca Marcon, Daniel Marzin, Pasquale Mosesso, Gerard Mulder, Agneta Oskarsson, Camilla Svendsen, Maria Anastassiadou, Maria Carfi, Siiri Saarma and Wim Mennes

Abstract

The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was requested by the European Commission according to Art. 29 1(a) of the Regulation (EC) No 178/2002 to carry out a review of existing literature on the safety of ethyl acrylate [FL-no: 09.037] when used as a flavouring substance. Ethyl acrylate [FL-no: 09.037] was evaluated in 2010 by EFSA in FGE.71 as a flavouring substance, based on the 2006 JECFA evaluation. The Panel concluded that ethyl acrylate was of no safety concern at estimated level of intake as a flavouring substance based on the Maximised Survey-Derived Daily Intake (MSDI) approach. The Panel has evaluated the new literature available and any previous assessments performed by JECFA (2006) and EFSA (2010). Moreover, new data on the use levels of ethyl acrylate as a flavouring substance have been provided. For use as a flavouring substance, the chronic dietary exposure estimated using the added portions exposure technique (APET), is calculated to be 3,545 µg/person per day for a 60-kg adult and 2,233 µg/person per day for a 15-kg 3-year-old child. Exposure from food contact materials may be up to 6,000 µg/person per day. The Panel considered that based on the available data, which covers all relevant genetic endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations) there is no concern with respect to genotoxicity of ethyl acrylate. The Panel evaluated the available carcinogenicity studies conducted in rats and mice and agreed with the NTP evaluation (1998) concluding that the forestomach squamous cell papilloma and carcinoma observed in rodents were not relevant to humans. Additionally, there was no evidence of systemic toxicity in short-term and subchronic toxicity studies. Therefore, the Panel concluded that there is no safety concern for the use of ethyl acrylate as a flavouring substance, under the intended conditions of use.

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: ethyl acrylate, [FL-no: 09.037], FGE.71, 140-88-5, genotoxicity, carcinogenicity, flavourings

Requestor: European Commission

Question number: EFSA-Q-2016-00426

Correspondence: fip@efsa.europa.eu
Panel members: Claudia Bolognesi, Laurence Castle, Kevin Chipman, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Roland Franz, Konrad Grob, Rainer Gürtler, Trine Husøy, Sirpa Kärenlampi, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Gilles Riviere, Jannavi Srinivasan, Maria de Fátima Tavares Poças, Vittorio Silano, Christina Tlustos, Detlef Wöflé and Holger Zorn.

Suggested citation: EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), Silano V, Bolognesi C, Castle L, Chipman K, Cravedi J-P, Engel K-H, Fowler P, Franz R, Grob K, Gürtler R, Husøy T, Kärenlampi S, Milana MR, Pfaff K, Riviere G, Srinivasan J, Tavares Poças MF, Tlustos C, Wöflé D, Zorn H, Benigni R, Binderup M-L, Brimer L, Marcon F, Marzin D, Mosesso P, Mulder G, Oskarsson A, Svendsen C, Anastasiadou M, Carfi M, Saarma S and Mennes W, 2017. Scientific opinion on safety of ethyl acrylate to be used as flavouring. EFSA Journal 2017;15(11):5012, 29 pp. https://doi.org/10.2903/j.efsa.2017.5012

ISSN: 1831-4732

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
Table of contents

Abstract ................................................................................................................................................... 1

1. Introduction .................................................................................................................................... 4
    1.1. Background and Terms of Reference as provided by the requestor ...................................................... 4
       1.1.1. Background .................................................................................................................................... 4
       1.1.2. Terms of Reference ......................................................................................................................... 4
    1.2. Interpretation of the Terms of Reference ........................................................................................... 4

2. Data and methodologies .................................................................................................................. 5

3. Procedure of the safety assessment .................................................................................................. 5
    3.1. Assessment ..................................................................................................................................... 5
    3.2. Technical data .................................................................................................................................. 5
    3.3. Information on existing evaluations from EFSA .................................................................................. 7
    3.4. Exposure ........................................................................................................................................ 7
      3.4.1. Concentration in processed and non-processed foods from natural sources ......................................... 7
      3.4.2. Chronic dietary exposure ................................................................................................................. 7
      3.4.3. Acute dietary exposure .................................................................................................................... 7
    3.5. Biological and toxicological data ....................................................................................................... 8
      3.6. Absorption, distribution, metabolism and excretion ............................................................................ 8
         3.6.1. Short-term and subchronic toxicity ................................................................................................... 8
         3.6.2. Genotoxicity .................................................................................................................................... 9
         3.6.3. Chronic toxicity and carcinogenicity .................................................................................................. 11
      3.6.4. Discussion ...................................................................................................................................... 12

4. Conclusions ..................................................................................................................................... 14

5. Recommendations ........................................................................................................................... 14

References ............................................................................................................................................... 14

Abbreviations ........................................................................................................................................... 15

Appendix A – Genotoxicity data evaluated in FGE.71 ............................................................................... 17
Appendix B – Previously not considered genotoxicity data ........................................................................... 21
Appendix C – Exposure ........................................................................................................................... 23
1. **Introduction**

1.1. **Background and Terms of Reference as provided by the requestor**

1.1.1. **Background**

The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and approval are required for flavouring substances.

The Union list of flavourings and source materials was established by Commission Implementing Regulation (EC) No 872/2012.

The substance benzophenone, [FL no. 07.032] (CAS No. 119-61-9) is currently included in this Union List. It is a substance which is not currently under evaluation. This substance is also known as diphenyl ketone. This substance was included in the Union list on the basis of the EFSA evaluation in FGE 69 of 2008. FGE 69 includes this substance. Benzophenone was evaluated by JECFA as a flavouring substance, with JECFA no. 831. The studies evaluated by IARC were not considered in the EFSA opinion on FGE 69. There may be also additional studies on the safety of this substance.

The substance ethyl acrylate, [FL no. 09.037], (CAS No. 140-88-5) was included in the Union list on the basis of the EFSA evaluation in FGE 71 of 2010. FGE.71 includes this substance. Ethyl acrylate was evaluated by JECFA as a flavouring substance, with JECFA no. 1351. The studies evaluated by IARC were not considered in the EFSA opinion of FGE.71. There may be also additional studies on the safety of this substance.

1.1.2. **Terms of Reference**

In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission requests the European Food Safety Authority (EFSA) to carry out a review of existing published literature on the safety of the flavouring substances benzophenone, [FL. No 07.032], (CAS No. 119-61-9) and ethyl acrylate, [FL-no: 09.037], (CAS No. 140-88-5), and advise on their safety when used as flavouring substances.

1.2. **Interpretation of the Terms of Reference**

Since benzophenone [FL- no: 07.032] and ethyl acrylate [FL-no: 09.037] are not structurally related and were evaluated in different FGEs (FGE.69 and FGE.71), they will be evaluated in separate opinions. The present document will address the question of the Commission on ethyl acrylate. Meanwhile, EFSA has also received information on use levels which will be taken into consideration. Considering the Term of Reference, the Panel will not address in this assessment, the exposure that may result from the use as food contact material.

In respect to the approach to be followed for the assessment of ethyl acrylate used as a flavouring substance, the Panel was of the view that previous assessments should be used as starting points for this scientific opinion. The previous assessment will be updated with new information that is connected to the concerns identified in the background (Section 1.1).

In the background (Section 1.1), it is mentioned that the studies evaluated by IARC in the report from 1999 on carcinogenicity of ethyl acrylate were not considered in the EFSA evaluation from 2010, and that there may be additional studies on the safety of ethyl acrylate when used as a flavouring substance. Thus, the present evaluation is mainly focusing on the genotoxicity and carcinogenicity of ethyl acrylate, in addition to considering any new data on toxicity, which may have an impact on the

---

1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.

2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.

3 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
safety assessment of ethyl acrylate as flavouring. Moreover, previous assessments of ethyl acrylate by 
JECFA (2006) and EFSA (EFSA CEF Panel, 2010a) are briefly presented.

According to the request from the Commission (Section 1.1), the present evaluation will be based
on available data on ethyl acrylate. Acrylic acid is a metabolite of ethyl acrylate and in that sense also
the safety of acrylic acid is included in this evaluation. However, the safety of exposure directly to
acrylic acid will not be evaluated in the present opinion, which according to the terms of reference will
address the use of ethyl acrylate as a flavouring substance.

2. Data and methodologies

The search for literature was done by EFSA on ethyl acrylate [FL-no: 09.037] to review existing
literature on the safety of this substance and to advise on its safety when used as flavouring
substance. A literature search was carried out through Web of Science database until August 2017,
using keywords “ethyl acrylate” or “140-88-5” and “genotox*”, “canc*”, “cancer”, “tumor*”, “toxicokin*”,
“metabol*”, “absorb*”, “distrib*”, “excret*”, and “reproduct*” while searching in “all databases”. Additional searches were carried out through Scopus database, using the keyword combination of
“ethyl acrylate” and “tox”, and the database of Decemis, using the keyword “140-88-5”.

3. Procedure of the safety assessment

3.1. Assessment

The Panel considered studies already evaluated (JECFA, 2006; EFSA CEF Panel, 2010a) and
additional studies from literature search. Except for genotoxicity, no new relevant studies were
identified for short-term toxicity, chronic toxicity and carcinogenicity.

3.2. Technical data

Information on the identity of the substance and specifications are based on data already described
in FGE.71 (EFSA CEF Panel, 2010a) and are presented in Table 1.
| FL-no | JECA-no | EU Register name | Structural formula | FEMA no COE no CAS no | Phys. Form Mol. Formula Mol. weight | Solubility (a) | Solubility in ethanol (b) | Boiling point, °C (c) | Melting point, °C | Assay minimum | Refrac. Index (d) | Spec. gravity (e) |
|-------|---------|------------------|---------------------|-----------------------|-------------------------------------|----------------|--------------------------|---------------------|-----------------|---------------|----------------|----------------|
| 09.037 | 1351    | Ethyl acrylate   |                     | 2418 245 140-88-5     | Liquid C5H8O2 100.12                | Slightly Soluble | Soluble                  | 99–101              | –               | IR 97%        | 1.403–1.409    | 0.916–0.919     |

FL-no: FLAVIS number; JECA: The Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract Service; ID: Identity; IR: infrared spectroscopy.

(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
3.3. Information on existing evaluations from EFSA

Ethyl acrylate [FL-no: 09.037] has been evaluated by JECFA (2006), EFSA considered this evaluation and concluded, in FGE.71, that ethyl acrylate is of no safety concern at estimated level of intake as flavouring substance based on the Maximised Survey-Derived Daily Intake (MSDI) approach (EFSA CEF Panel, 2010a).

Ethyl acrylate was evaluated as a substance in food contact materials (FCM) by the Scientific Committee for food (SCF, 1999). They established a group temporary tolerable daily intake (TDI) of 0.1 mg/kg body weight (bw) for several acrylates, expressed as acrylic acid. The temporary TDI was based on data from experimental animals exposed to acrylic acid. Based on this TDI, a specific migration limit (SML) of 6 mg/kg of food was calculated for the group of substances that share acrylic acid as a common metabolite/degradation product.

In Regulation (EU) No 10/20114, ethyl acrylate is an approved monomer for use in FCM with a group SML for the sum of substances that have acrylic acid as a common metabolite/degradation product of 6 mg/kg of food.

3.4. Exposure

3.4.1. Concentration in processed and non-processed foods from natural sources

Ethyl acrylate [FL-no: 09.037] has been reported to occur in passion fruit, pineapple, Beaufort cheese and durian (IARC, 1999a, Triskelion, 2017). Quantitative data are reported for ethyl acrylate in pineapple (0.01 mg/kg) (Triskelion, 2017).

3.4.2. Chronic dietary exposure

The exposure assessment to be used in the Procedure for the safety evaluation of the candidate substance is the chronic added portions exposure technique (APET) estimate (EFSA CEF Panel, 2010b). The chronic APET for ethyl acrylate has been calculated for adults and children (see Table 2 and Appendix C). The chronic APET calculation is based on the combined normal occurrence level.

The Panel noted that the contribution from natural occurrence of ethyl acrylate to the APET is negligible compared to the added flavouring substance.

Table 2: APET – Chronic dietary exposure

| Chronic APET | Added(a) | Other dietary sources(b) | Combined(c) |
|--------------|----------|--------------------------|------------|
|              | µg/kg bw per day | µg/person per day | µg/kg bw per day | µg/person per day | µg/kg bw per day | µg/person per day |
| Adults(d)    | 59.1     | 3,545                    | 0.23        | 14.0        | 59.1 | 3,545 |
| Children(e)  | 149      | 2,233                    | 0.59        | 8.85        | 149 | 2,233 |

APET: added portions exposure technique; bw: body weight.
(a): APET Added is calculated on the basis of the normal amount of flavour added to a specific food category.
(b): APET Other Dietary Sources is calculated based on the natural occurrence of the flavouring in a specified food category.
(c): APET Combined is calculated based on the combined amount of added flavouring and naturally occurring flavouring in a specified food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year old child with a 15 kg bw is considered representative.

The Panel noted that exposure to ethyl acrylate may also occur from FCM (SML 6 mg/kg food, as acrylic acid, corresponding to a maximum exposure of 6 mg/person per day; see Section 3.3).

3.4.3. Acute dietary exposure

Acute exposure is not evaluated, because this opinion addresses only chronic exposure.

---

4 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact with food. OJ L 12, 15.1.2011, p. 1-89.
3.5. Biological and toxicological data

The toxicity of ethyl acrylate has been evaluated by JECFA in 2006 and concerning genotoxicity by EFSA (EFSA CEF Panel, 2010a). The carcinogenicity was evaluated by IARC in 1999a. Brief summaries of the previous evaluations will follow below and data not previously considered will be presented.

3.6. Absorption, distribution, metabolism and excretion

Ethyl acrylate is the ethyl ester of acrylic acid. Aliphatic esters formed from 2-alkenoic acids are generally rapidly hydrolysed to respective alcohols and carboxylic acids by carboxylesterases. Thus, ethyl acrylate is hydrolysed to acrylic acid and ethanol, which will participate in biochemical pathways, including the fatty acid pathway and tricarboxylic acid cycle (see review by JECFA, 2006).

**In vitro studies**

Miller et al. (1981) compared the rate of hydrolysis of ethyl acrylate in homogenates of different tissues and found the highest rate in liver, followed by whole blood, lung and kidney. In the liver homogenate, the hydrolysis rate of ethyl acrylate was 26.8 nmol/min. Potter and Tran (1992) demonstrated that ethyl acrylate reacts with both glutathione (GSH) and protein in vitro.

**In vivo studies**

14C-Ethyl acrylate has been used for metabolic studies (DeBethizy et al., 1987). Rats were administered single oral doses of 2, 20 and 200 mg/kg bw and radioactivity was followed during 72 h. A rapid and high absorption was demonstrated and most of the radioactivity was exhaled as CO2 (52–62% of dosed radioactivity) and almost all during the first 10 h after administration. The detection of 3-hydroxypropionic acid as a urinary metabolite led to the suggestion by the authors, that acrylic acid was incorporated into propionic acid metabolism, explaining the rapid formation of carbon dioxide. In urine two metabolites derived from GSH conjugation were also detected. At the two lower doses of ethyl acrylate, non-protein sulfhydryl (NPSH) content decreased significantly at the dosing site, forestomach and glandular stomach, but not in the liver. NPSH, mainly GSH, cysteine, coenzyme A and other thiols in the gastric mucosa, are suggested to play an important role in the protection of gastric mucosa against chemically-induced lesions (Nagy et al., 2007).

Oral dosing of rats with ethyl acrylate was performed in a study by Frederick et al. (1992) to validate a physiologically based pharmacokinetic and pharmacodynamics model for ethyl acrylate. The predicted very rapid metabolism was verified and consistent with the finding that no ethyl acrylate could be detected in tissues. The model also predicted glutathione depletion in forestomach.

Overall, ethyl acrylate is rapidly absorbed, metabolised, incorporated into endogenous biochemical pathways and excreted.

3.6.1. Short-term and subchronic toxicity

A single dose of 100, 200 or 400 mg/kg bw ethyl acrylate administered by gavage to F344 rats caused mucosal and submucosal oedema and vacuolisation of the tunica muscularis in the forestomach and mild submucosal oedema in the glandular stomach (Ghanayem et al., 1985). No gastric effects were observed after equivalent subcutaneous or intraperitoneal (i.p.) doses. After 2 or 4 consecutive daily doses of 200 mg/kg bw similar effects were observed, and in addition submucosal inflammation, mucosal erosions or ulcers in both portions of the stomach. There was no systemic toxicity. The same authors (Ghanayem et al., 1986) also studied the recovery of the lesions in rats after 14 daily gavage doses of 100 or 200 mg/kg bw ethyl acrylate. After 14 days of exposure, the glandular stomach was normal in all animals and appeared to have adapted to resist the toxicity of ethyl acrylate. The forestomach exhibited dose-dependent lesions, which were recovered in the low dose group at 14 days following the last dose, while in the high dose group mucosal hyperplasia was still present in the forestomach at 4 weeks after last exposure.

Male F344/N rats were dosed with ethyl acrylate either by gavage at doses from 2 to 200 mg/kg bw daily for 2 weeks or via drinking water at concentrations from 200 to 4,000 mg/L (corresponding to 23–369 mg/kg bw/day, according to the authors) (Frederick et al., 1990). A dose-dependent increase in irritation of the forestomach was observed in the animals dosed by gavage, while the animals dosed via drinking water had a much lower incidence and less severe lesions at the corresponding dose levels. There were no lesions in the glandular stomach. Severe depletion of NPSH...
was observed in the forestomach at gavage doses ≥ 100 mg/kg bw, while no significant depletion was seen after administration via drinking water. The NPSH depletion in glandular stomach and liver were lower, and not at levels generally associated with toxicity. The authors suggested that the depletion of NPSH in the rat forestomach was causally related to the histopathology observed at relatively high doses. Thus, at doses of 100 mg/kg bw per day or greater by gavage, the NPSH content was severely depleted (below 25% of the initial concentration) and moderate to marked hyperplasia was observed together with ulceration and erosion of the forestomach epithelium. Minimal depletion of NPSH, producing minimal to mild hyperplasia, was reported at 20–50 mg/kg bw. At 10 mg/kg bw and less, no significant NPSH depletion and no histopathological findings were reported.

To design the 2-year carcinogenesis study on ethyl acrylate, the NTP performed several 14-day and 13-week gavage studies in B6C3F1 mice and F344/N rats (NTP, 1986). The principal toxic effect in the 14-day studies was in the forestomach of both sexes in mice and rats. There was no evidence of systemic toxicity. The lowest dose where histological lesions in the forestomach were detected was 400 mg/kg bw in rats and 200 mg/kg bw in mice.

Sustainability of forestomach hyperplasia was studied in rats treated with ethyl acrylate for 13 weeks with gavage doses of 100 or 200 mg/kg bw per day (Ghanayem et al., 1991). Severe hyperplasia of the forestomach was observed after 13 weeks. No effects were detected in the glandular stomach or liver. A significant decline in incidence and severity of the hyperplasia was reported in rats after a recovery period of 8 weeks without treatment and a further decline in effects were seen after 13 weeks.

Overall, severe irritation of the forestomach and mild oedema of the glandular stomach resulted from a single dose of ethyl acrylate, administered by gavage. In short-term and subchronic gavage studies, histological lesions were observed in the forestomach but not in the glandular stomach. The histopathological lesions in the forestomach were associated to NPSH depletion. After cessation of exposure, there was a dose-dependent recovery of the forestomach lesions. Exposure of ethyl acrylate via drinking water caused lower incidence and less severe forestomach lesions. No gastric effects were observed after parenteral administrations. There was no evidence of systemic toxicity.

### 3.6.2. Genotoxicity

**Summary of in vitro data assessed in FGE.71**

*In vitro* genotoxicity studies described below were considered in FGE.71 (EFSA CEF Panel, 2010a), based on JECFA evaluation (2006) and are summarised in Appendix A, Table A.1.

Negative results were reported in Ames assays when *Salmonella* Typhimurium strains (TA97, TA98, TA100, TA1535, TA1537 and TA1538) were incubated with ethyl acrylate [FL-no: 09.037] at concentrations up to 10,000 μg/plate (Ishidate et al., 1981; Waegemaekers and Bensink, 1984; Tennant et al., 1987; Zeiger et al., 1992).

No evidence of mitotic chromosomal loss was obtained when ethyl acrylate at concentrations up to 1,095 μg/mL was incubated with *Saccharomyces cerevisiae* strain D61.M. Under a cold shock regimen, evidence of mitotic recombination was reported (Zimmermann and Mohr, 1992).

In the standard assay for forward mutation in mouse lymphoma cells, ethyl acrylate gave uniformly positive results in the absence of metabolic activation when tested with mouse lymphoma L5178Y Tk+ cells at cytotoxic concentrations (37.5–50 μg/mL) associated with a reduction of the relative total growth by 50–60% (Tennant et al., 1987; McGregor et al., 1988; Moore et al., 1988; Ciaccio et al., 1998). In assays for clastogenicity, ethyl acrylate elicited increases in sister chromatid exchanges (SCE) and chromosomal aberrations (CA) in Chinese hamster ovary (CHO) cells with metabolic activation, but showed no evidence of clastogenicity in the absence of metabolic activation (Loveday et al., 1990). The clastogenic potential was unaffected by changes in harvest time (Loveday et al., 1990). Ethyl acrylate induced an increase in SCE and CA in mouse lymphoma cells in a dose-dependent manner, beginning at 20 μg/mL, in the absence of metabolic activation (Moore et al., 1988). An increase in SCE and CA in CHO cells was also reported in another study with ethyl acrylate at concentrations of 150 and 299 μg/mL, respectively, with metabolic activation (Tennant et al., 1987). There was no evidence of clastogenicity in the absence of metabolic activation (Tennant et al., 1987). Increases in CA were reported at 9.8 μg/mL in Chinese hamster cells with or without metabolic activation (Ishidate et al., 1981).

**In vitro data not previously considered**

*In vitro* genotoxicity studies, previously not considered in the EFSA evaluation are summarised in Appendix B, Table B.1.
Ethyl acrylate tested up to 5,000 µg/plate was negative in S. Typhimurium strain TA102 (Kirkland et al., 2016).

Ethyl acrylate tested up to 2,000 µg/plate in the S. Typhimurium strain YG7108 (otr-, ada-) (mutant of TA1535 strain deficient in methyl transferase), transformed with the plasmid pin3EB5, encoding for a complete electron transport chain, comprising P450 reductase, cytochrome b5 and cytochrome P450 2E1, did not induce any significant increase of the revertants (Emmert et al., 2006).

A number of studies are available on in vitro micronucleus (MN) assay in different rodent (V79, CHL, CHO and LS178Y) and human cell lines, p53 competent and p53 mutated, in the presence and absence of cytochalasin B (Fowler et al., 2012a,b; Whitwell et al., 2015). Ethyl acrylate was tested at different concentrations up to 55% of cytotoxicity for 3 h followed by recovery and for 24 h without recovery. The results showed increases of frequencies of micronucleated cells in rodent p53-deficient cell lines. Following treatment of human cell lines WIL2-NS (with mutated p53) and TK6 (with wild-type p53) using the cytochalasin-blocked cytokinesis assay, the majority of concentrations tested resulted in micronucleated cell frequencies similar to the control values, with single exceptions, characterised by a marginal increase at intermediate concentrations.

Using an alternative protocol in the absence of cytochalasin B following treatment of WIL2-NS and TK6 cells with ethyl acrylate, normal frequencies of mononucleated cells with MN were observed for all concentrations including those inducing 53% and 66% cytotoxicity, respectively, fulfilling the criteria for clear negative responses. In contrast, small but statistically significant increases in MN frequency were observed at the highest two concentrations analysed following treatment of LS178Y cells. Significant increases in caspase activity (greater than threefold over the vehicle control) associated with high level of toxicity were observed in TK6 cells after treatment with ethyl acrylate, suggesting apoptosis as a mechanism of induction of micronuclei frequencies (Fowler et al., 2012a,b; Whitwell et al., 2015).

**Summary of in vivo data assessed in FGE.71**

*In vivo* genotoxicity studies described below were considered in FGE.71 (EFSA CEF Panel, 2010a), based on JECFA evaluation (2006) and are summarised in Appendix A, Table A.1.

Single oral doses of ethyl acrylate at concentrations up to 4% were administered to male F344 rats (Morimoto et al., 1990). The forestomach exhibited oedema and inflammation, but no DNA damage was detected by alkaline elution.

In an *in vivo*–*in vitro* assay for clastogenicity, C57BL/6 male mice were given ethyl acrylate at doses of 0, 125, 250, 500 or 1,000 mg/kg bw by i.p. injection (Kligerman et al., 1991). Twenty-four hours later, animals were sacrificed, splenocytes were isolated and concanavalin A was added to stimulate cell division. In half cultures, bromodeoxyuridine was added for the analysis of CA in the first division cells, and SCE in the second division cells. In the remaining cultures, cytochalasin B was added for the scoring of MN in binucleated cells. No significant increase of CA and SCE was reported, while ethyl acrylate did induce a statistically significant increase of binucleated cells with MN (less than twofolds with respect to the control value) only at the highest dose (1,000 mg/kg bw); according to the study authors, this increase was apparently due to a relatively high response in one of five animals. The highest dose tested in this study is fivefold higher than the highest dose (200 mg/kg bw) used in the carcinogenicity study by the National Toxicology Program (1986) (Kligerman et al., 1991).

Although an early report (Przybojewska et al., 1984) indicated that ethyl acrylate was genotoxic in a standard MN test in mice, subsequent studies (Ashby et al., 1989; Kligerman et al., 1991; Harra et al., 1994; Morita et al., 1997) confirmed that ethyl acrylate exhibits no genotoxic potential in this assay. An increase in the incidence of polychromatic erythrocytes (PCE) with MN was reported in bone marrow of BALB/C male mice treated with ethyl acrylate at doses of 225–1,800 mg/kg bw by i.p. injection in two doses separated by 24 h. A statistically significant decrease of the ratio between PCEs and normochromatic erythrocytes (NCEs) was observed in the same range of doses, indicating bone marrow toxicity (Przybojewska et al., 1984). There was no evidence of increase in MN cells collected 24 h after groups of six BDF1 male mice were given ethyl acrylate as a single or two doses at 0, 188, 375 or 750 mg/kg bw by oral gavage or when ethyl acrylate was administered as a single dose at 0, 375, 500 or 750 mg/kg bw by i.p. injection. A statistically significant reduction of reticulocyte percent after double oral gavage and i.p. administration at 750 mg/kg was reported (Hara et al., 1994). In another MN test, groups of five male and five female C57BL/6 mice were given ethyl acrylate as a single i.p. dose at 461 or 738 mg/kg bw and samples were collected at 24, 48 (738 mg/kg bw dose only) and 72 h (738 mg/kg bw dose only) (Ashby et al., 1989). In subsequent experiments, groups of 5–10 male C57BL/6 and BALB/c mice were given ethyl acrylate at a dose of 738 or 812 mg/kg bw in two doses administered by i.p. injection within 24 h, and erythrocytes were sampled at 30 h. In none of these
experiments, there was any evidence of increase in MN PCE in bone marrow of mice (Ashby et al., 1989). Negative results were obtained for MN induction when groups of six male BDF1 mice were given ethyl acrylate either as a single oral dose (188, 375 or 750 mg/kg bw) or a single intraperitoneal dose (188 or 375 mg/kg bw) and samples of bone marrow were collected after 24 h (Morita et al., 1997).

In an assay for mutagenicity in vivo in Drosophila melanogaster, there was no evidence of increase in sex-linked recessive lethals in three successive broods obtained from Basc virgin females mated with Canton-S wild-type males either injected with ethyl acrylate at a concentration of 20,000 mg/kg or fed a solution containing ethyl acrylate at a concentration of 40,000 mg/kg for 3 days. In a second experiment, there was no evidence of mutagenicity when D. melanogaster were fed a solution containing ethyl acrylate at a concentration of 18,000 or 20,000 mg/kg (Valencia et al., 1985). 

In vivo data not previously considered

No new data are available.

Conclusions on genotoxicity

Overall, the Panel considered that based on the available data, which covers all relevant genetic endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations), there is no concern with respect to genotoxicity of ethyl acrylate.

3.6.3. Chronic toxicity and carcinogenicity

Carcinogenesis studies of ethyl acrylate was performed by NTP in B6C3F1 mice and F344/N rats given the test compound in corn oil by gavage at doses of 100 and 200 mg/kg bw per day, 5 days per week, for 103 weeks (NTP, 1986). There was no evidence of toxicity at any other sites than the forestomach. A dose-related increase in the incidences of hyperkeratosis, hyperplasia and inflammation of the forestomach were reported in both sexes and both species, in addition to a statistically significant positive trend in the incidence of squamous cell carcinoma and papilloma in the forestomach. The incidence of tumours in the forestomach was higher in rats than in mice, which was explained by a twofold higher concentration of ethyl acrylate in the gavage solution for rats than for mice, in the 2-year study. Statistically significant negative trends were reported for several tumours, such as hepatocellular carcinoma, follicular cell tumour of the thyroid and lymphocytic lymphoma in male mice. The conclusions from NTP (1986) were 'Under the conditions of these studies, ethyl acrylate was carcinogenic for the forestomach of F344/N rats and B6C3F1 mice, causing squamous cell carcinomas in male rats and male mice, and squamous cell papillomas or carcinomas (combined) in male and female rats and mice. Evidence for carcinogenicity was greater in males than in females. Ethyl acrylate also caused irritation of the forestomach mucosa in male and female rats and mice'.

This conclusion was later modified (NTP, 1998), with the following recommendation ‘It is recommended that ethyl acrylate be delisted from the Report on Carcinogens because the forestomach tumors, induced in animal studies, were seen only when the chemical was administered by gavage at high concentrations of ethyl acrylate, that induced marked local irritation and cellular proliferation and because significant chronic human exposure to high concentrations of ethyl acrylate monomer is unlikely'.

Ghanayem et al. (1993, 1994) studied the time required for sustained forestomach hyperplasia to produce neoplastic lesions in F344 rats administered ethyl acrylate at 200 mg/kg bw per day, 5 days per week, by gavage for 6 or 12 months. The increase in epithelial hyperplasia of the forestomach sustained as long as the exposure continued. However, the hyperplasia regressed and no neoplasms developed, when exposure was stopped after 6 months and the animals were allowed to recover until they were sacrificed at 24 months of age. In contrast, forestomach squamous cell carcinoma developed in rats treated for 12 months and allowed to recover for 9 months.

Acrylic acid, a metabolite of ethyl acrylate, was given to Wistar rats during 12 months in drinking water, containing 120, 800, 2,000 or 5,000 mg/L, providing doses of about 9, 61, 140 and 331 mg/kg bw per day, according to the authors (Hellwig et al., 1993). The two highest doses led to reduced consumption of drinking water, indicating palatability problems. There were no indications of systemic toxicity or carcinogenicity. Another study was performed in rats for 26 (males) and 29 (females) months with drinking water concentrations of 120, 400 or 1,200 mg/L, providing doses of 8, 27 or 78 mg/kg bw per day. There were no indications of toxic changes or carcinogenic potential.

Overall, increases in forestomach squamous cell papilloma and carcinoma were reported in rats and mice, when ethyl acrylate was administered via gavage. The neoplasms were preceded by extreme
3.6.4. Discussion

The NTP carcinogenicity studies from 1986 concluded that ethyl acrylate administered by gavage was carcinogenic for the forestomach of mice and rats due to increases in forestomach squamous cell papilloma and carcinoma. The lesions were related to the concentration of ethyl acrylate in dosing solutions. Severe irritation of the forestomach was seen after single oral administration of ethyl acrylate. Hyperkeratosis, inflammation and hyperplasia of the forestomach were observed in subchronic and 2-year gavage studies. There were no gastric lesions after parenteral administration and no evidence of systemic toxicity in any of the studies. The Panel considered the observed local forestomach lesions to be a consequence of the known irritating properties of ethyl acrylate.

The conclusion on carcinogenicity of ethyl acrylate from the NTP studies was revised in 1998, when NTP recommended ethyl acrylate to be 'delisted from the Report on Carcinogens because the forestomach tumors, induced in animal studies, were seen only when the chemical was administered by gavage at high concentrations of ethyl acrylate, that induced marked local irritation and cellular proliferation and because significant chronic human exposure to high concentrations of ethyl acrylate monomer is unlikely'. This conclusion was supported by Williams and Iatropoulos (2009), who further emphasised that the route and rate of ethyl acrylate exposure in rodents for forestomach neoplasia are not relevant to humans, since humans do not have forestomach and are not exposed to ethyl acrylate by oral bolus.

Based on experimental data (publications up to 1993) in rodents showing lesions and carcinoma of forestomach, IARC (1999a) classified ethyl acrylate as possibly carcinogenic to humans (Group 2B). It should be noted, that IARC monographs are intended to be hazard evaluations, that is to identify whether a substance can be associated with the development of cancer, regardless of the dose or exposure conditions at which an increased risk occur (Goodman and Lynch, 2017). In the mechanistic considerations, IARC (1999a) noted that ethyl acrylate was clastogenic \textit{in vitro}, but not \textit{in vivo}.

The predictive value of rodent forestomach tumours in evaluating carcinogenic risks to humans was discussed by IARC (1999b), which considered in particular exposure conditions and tissue specificity. Exposure conditions should be considered, especially if oral gavage is used, because it can result in high local concentration of the test substance in the forestomach and prolonged exposure of the epithelial tissue. 'Agents that produce tumors in rodent forestomach only after prolonged exposure through non-DNA reactive mechanisms, may be less relevant to humans because human exposure would have to overcome time-integrated dose thresholds to result in a carcinogenic response' (IARC, 1999b).

In the present safety evaluation, genotoxicity of ethyl acrylate was assessed from all available data, both previously assessed and previously not considered. Ethyl acrylate was negative in bacterial reverse mutation assays. Ethyl acrylate resulted positive when tested in some \textit{in vitro} assays for gene mutation and CA in mammalian cells, however, in \textit{in vivo} studies no genotoxicity effects were observed as also reported for other acrylates (Johannsen et al., 2008). Therefore, based on the available data, which covers all relevant genetic endpoints (i.e. gene mutations, structural and numerical chromosomal aberrations), the Panel considers that there is no concern with respect to genotoxicity of ethyl acrylate.

The Panel agrees with the NTP re-evaluation (1998) and considers that the forestomach squamous cell papilloma and carcinoma are preceded by extreme sustained irritation of the epithelium, which is reversible when exposure is stopped after 6 months but not after 12 months. No lesions are observed in the glandular stomach. Moreover, in short-term, subchronic and chronic toxicity studies, there was no evidence of systemic toxicity.

The initiating events for the effects in the forestomach involve depletion of NPSH, which was observed in the forestomach at gavage doses >100 mg/kg bw per day, while no significant depletion was seen after administration via drinking water at 200–4,000 mg/L (Frederick et al., 1990). The depletion of NPSH in the rat forestomach was related to the histopathology observed at relatively high doses. At 10 mg/kg bw and less, no significant NPSH depletion and no histopathological findings were reported.

The estimated chronic dietary exposure of ethyl acrylate in adults and children were 60 and 150 µg/kg bw per day, respectively, calculated by the APET approach, with minimal contribution from natural occurring flavour in food. Maximum exposure from FCM may be up to 100 µg/kg bw per day.

The Panel considers that the forestomach tumours, observed in rodents, are not a relevant toxicological endpoint to humans since they are not exposed to ethyl acrylate by oral bolus. Furthermore, there is an absence of correlation between forestomach in rats and oesophageal lesions.
in humans, as reported in the reviews by Wester and Kroes (1988) and Proctor et al. (2007). The Panel considers the effects of ethyl acrylate in the forestomach to be local and dependent on the concentration of ethyl acrylate. The concentration and exposure time, which induce the irritating effect in the forestomach would not be reached by exposure to ethyl acrylate via the use as a flavouring. Consequently, the Panel considers that the calculated chronic dietary exposure in adults and children would not be of safety concern.

4. Conclusions

The Panel concluded that ethyl acrylate is not genotoxic in vivo and that carcinogenic effects observed in rodent studies are not relevant to humans. Therefore, the Panel concluded that there is no safety concern for the use of ethyl acrylate as a flavouring substance in food, under the intended conditions of use.

5. Recommendations

The Panel takes note of other potential sources of dietary exposure such as from FCM. Exposure from plastic FCM could be up to the temporary TDI of 100 µg/kg bw per day, bringing the potential exposure from both plastic and flavouring above this TDI. The Commission may wish to take this into account.

References

Ashby J, Richardson CR and Tinwell H, 1989. Inactivity of ethyl acrylate in the mouse bone marrow micronucleus assay. Mutagenesis, 4, 283–285.
Ciaccio PJ, Gicquel E, O’Neill PJ, Scribner HE and Vandenberghe YL, 1998. Investigation of the positive response of ethyl acrylate in the mouse lymphoma genotoxicity assay. Toxicological Sciences, 46, 324–332.
DeBethizy JD, Udinsky JR, Scribner HE and Frederick CB, 1987. The disposition and metabolism of acrylic acid and ethyl acrylate in male Sprague-Dawley rats. Fundamental and Applied Toxicology, 8, 549–561.
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2010a. Scientific Opinion on Flavouring Group Evaluation 71 (FGE.71): Consideration of aliphatic, linear, alpha, beta-unsaturated carboxylic acids and related esters evaluated by JECFA (63rd meeting) structurally related to esters of branched- and straight-chain unsaturated carboxylic acids. Esters of these and straight-chain aliphatic saturated alcohols evaluated by in FGE.05Rev2 (2009). EFSA Journal 2010;8(2):1401, 35 pp, https://doi.org/10.2903/j.efsa.2010.1401.
EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2010b. Guidance on the data required for the risk assessment of flavourings. EFSA Journal 2010;8(6):1623, 38 pp, https://doi.org/10.2093/j.efsa.2010.1623.
Emmert B, Bürger J, Keuch K, Müller M, Emmert S, Hallier E and Westphal GA, 2006. Mutagenicity of cytochrome P450 2E1 substrates in the Ames test with the metabolic competent S. typhimurium strain YG7108pin3ERb5. Toxicology, 228, 66–76.
FAO/WHO, 2008. Evaluation of certain food additives. Sixty-ninth report of the joint FAO/WHO expert committee on food additives. Rome, 17–26 June 2008. WHO technical report series, No 952.
Fowler P, Smith K, Young J, Jeffrey L, Kirkland D, Pfuhler S and Carmichael P, 2012a. Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. I. Choice of cell type. Mutation Research, 742, 11–25.
Fowler P, Smith R, Smith K, Young J, Jeffrey L, Kirkland D, Pfuhler S and Carmichael P, 2012b. Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. II. Importance of accurate toxicity measurement. Mutation Research, 747, 104–117.
Frederick CB, Hazleton GA and Frantz D, 1990. The histopathological and biochemical response of the stomach of male F344/N rats following two weeks of oral dosing with ethyl acrylate. Toxicologic Pathology, 18, 247–256.
Frederick CB, Potter DW, Chang-Mateu MI and Andersen ME, 1992. A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. Toxicology and Applied Pharmacology, 114, 246–260.
Ghanayem BI, Maronpot RR and Matthews HB, 1985. Ethyl acrylate-induced gastric toxicity. I. Effect of single and repetitive dosing. Toxicology and Applied Pharmacology, 80, 323–335.
Ghanayem BI, Maronpot RR and Matthews HB, 1986. Ethyl acrylate-induced gastric toxicity. III. Development and recovery of lesions. Toxicology and Applied Pharmacology, 83, 576–583.
Ghanayem BI, Matthews HB and Maronpot RR, 1991. Sustainability of forestomach hyperplasia in rats treated with ethyl acrylate for 13 weeks and regression after cessation of dosing. Toxicologic Pathology, 19, 273–279.
Ghanayem BI, Sanchez IM, Maronpot RR, Elwell MR and Matthews HB, 1993. Relationship between the Time of Sustained Ethyl Acrylate Forestomach Hyperplasia and Carcinogenicity. Environmental Health Perspectives, 101, 277–280.

Ghanayem BI, Sanchez IM, Matthews HB and Elwell MR, 1994. Demonstration of a temporal relationship between ethyl acrylate-induced forestomach cell proliferation and carcinogenicity. Toxicologic Pathology, 22, 497–509.

Goodman J and Lynch H, 2017. Improving the International Agency for Research on Cancer’s consideration of mechanistic evidence. Toxicology and Applied Pharmacology, 319, 39–46.

Hara T, Katoh M, Horiya N and Shibuya T, 1994. Ethyl acrylate is negative in the bone marrow micronucleus test using BDF male mice. Environmental Mutagen Research Communications, 16, 211–215.

Haworth S, Lawlor T, Mortelmans K, Speck W and Zeiger E, 1983. Salmonella mutagenicity test results for 250 chemicals. Environmental Mutagenesis, Suppl. 1, 3–142.

Hellwig J, Deckardt K and Freisberg KO, 1993. Subchronic and chronic studies of the effects of oral administration of acrylic acid to rats. Food and Chemical Toxicology, 31, 1–8.

IARC (International Agency for Research on Cancer), 1999a. IARC monographs on the evaluation of carcinogenic risks to humans, volume 71. Available online: http://monographs.iarc.fr/ENG/Monographs/vol71/mono71.pdf

IARC (International Agency for Research on Cancer), 1999b. IARC technical publication no 39. Predictive Value of Rodent Forestomach and Gastric Neuroendocrine Tumours in Evaluating Carcinogenic Risks to Humans. Views and Expert Opinions of an IARC Working Group Lyon, 29 November–1 December 1999.

Ishidate M, Sofuni T and Yoshikawa K, 1981. Chromosomal aberration tests in vitro as a primary screening tool for environmental mutagens and/or carcinogens. In: Inui N, Kuroki T, Yamada MA and Heidelberger C (eds). Mutation, promotion and transformation in vitro. GANN Monograph on Cancer Research. Japanese Scientific Society Press, Tokyo, Japan. pp. 95–108.

IJECA, 2006. Safety evaluation of certain food additives and contaminants. Sixty-third meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO Food Additives Series: 54. IPCS, WHO, Geneva.

Johannsen FR, Vogt B, Waite M and Deskin R, 2008. Mutagenicity assessment of acrylate and methacrylate compounds and implications for regulatory toxicology requirements. Regulatory Toxicology and Pharmacology, 50, 322–335.

Kirkland D, Kasper P, Martus H-J, Müller L, van Benthem J, Madia F and Corvi R, 2016. Updated recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests. Mutation Research, 795, 7–30.

Kligerman AD, Atwater AL, Bryant MF, Erexson GL, Kwanyuen P and Dearfield KL, 1991. Cytogenetic studies of ethyl acrylate using C57BL/6 mice. Mutagenesis, 6, 137–141.

Loveday KS, Anderson BE, Resnick MA and Zeiger E, 1990. Chromosome aberration and sister chromatid exchange tests in chinese hamster overy cells in vitro. V. Results with 46 chemicals. Environmental and Molecular Mutagenesis, 16, 272–303.

McGregor DB, Brown A, Cattanach P, Edwards I, McBride D, Riach C and Caspary WJ, 1988. Responses of the L5178Y tk-/-tk- mouse lymphoma cell forward mutation assay: III. 72 coded chemicals. Environmental and Molecular Mutagenesis, 12, 85–153.

Miller RR, Ayres JA, Rampy LW and McKenna MJ, 1981. Metabolism of acrylate esters in rat tissue homogenates. Fundamental and Applied Toxicology, 1, 410–414.

Moore MM, Amtower A, Doerr CL, Brock KH and Dearfield KL, 1988. Genotoxicity of acrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate, and ethyl methacrylate in L5178Y mouse lymphoma cells. Environmental and Molecular Mutagenesis, 11, 49–63.

Morimoto K, Tsuji K, Osawa R and Takahashi A, 1990. DNA damage test in forestomach squamous epithelium of F344 rat following oral administration of ethyl acrylate. Eisei Shikenjo, 08, 125–128 (In Japanese).

Morita T, Asano N, Awogi T, Sasaki YF, Sato S, Shimada H, Sutou S, Suzuki T, Wakata A, Sofuni T and Hayashi M, 1997. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B). The summary report of the 6th collaborative study by CSGMT/JEMS. Mutation Research, 389, 3–122.

Nagy L, Nagata M and Szabo S, 2007. Protein and non-protein sulfhydryls and disulfides in gastric mucosa and liver after gastrotoxic chemicals and sucralfate: Possible new targets of pharmacologic agents. World Journal of Gastroenterology, 13(14), 2053–2060.

NTP (National Toxicology Program), 1986. Carcinogenesis studies of ethyl acrylate (CAS No. 140-88-5) in F344/N rats and B6C3F1 mice (gavage studies). National Toxicology Program, technical report series No. 259.

NTP (National Toxicology Program), 1998. Report on carcinogens background document for ethyl acrylate. Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee. Available online: https://ntp.niehs.nih.gov/ntp/newhomerc/other_background/ethylacryl_noapps_508.pdf

Potter DW and Tran TB, 1992. Rates of ethyl acrylate binding to glutathione and protein. Toxicology Letters, 62, 275–285.
Proctor DM, Gatto M, Hong SJ and Allmneni KP, 2007. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicological Sciences, 98, 313–326.

Przybojewska B, Dziubaltowska E and Kowalski Z, 1984. Genotoxic effects of ethyl acrylate and methyl acrylate in the mouse evaluated by the micronucleus test. Mutation Research, 135, 189–191.

SCF (Scientific Committee for food), 1999. European Commission, Food science and techniques. Reports of the Scientific Committee for Food (42nd series). Compilation of the evaluations of the scientific committee for food on certain monomers and additives used in the manufacture of plastics materials intended to come into contact with foodstuffs until 21 March 1997. Directorate-General Consumer Policy and Consumer Health Protection, 1999.

Tennant RW, Margolin BH, Shelby MD, Zeiger E, Haseman JK, Spalding J, Caspary W, Resnick M, Stasiewicz S, Anderson B and Minor R, 1987. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science, 236, 933–941.

Triskelion, 2017. VCF online. Volatile Compounds in Food. Nijssen B, van Ingen-Visscher K, Donders J (eds.). Database version 16.3. Triskelion, Zeist, The Netherlands. 1992-2017.

Valencia R, Mason JM, Woodruff RC and Zimmering S, 1985. Chemical mutagenesis testing in Drosophila. III. Results of 48 coded compounds tested for the National Toxicology Program. Environmental and Molecular Mutagenesis, 7, 325–348.

Waegemaekers THJM and Bensink MPM, 1984. Non-mutagenicity of 27 aliphatic acrylate esters in the Salmonella-microsome test. Mutation Research, 137, 95–102.

Wester PW and Kroes R, 1988. Forestomach carcinogens: pathology and relevance to man. Toxicologic Pathology, 16, 165–171.

Whitwell J, Smith R, Jenner K, Lyon H, Wood D, Clements J, Aschcroft-Hawley K, Gollapudi B, Kirkland D, Lorge E, Pfuhler S, Tanir JY and Thybaud V, 2015. Relationships between p53 status, apoptosis and induction of micronuclei in different human and mouse cell lines in vitro: Implications for improving existing assays. Mutation Research, 789–790, 7–27.

Williams GM and Iatropoulos MJ, 2009. Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate. Regulatory Toxicology and Pharmacology, 53, 6–15.

Zeiger E, Anderson B, Haworth S, Lawlor T and Mortelmans K, 1992. Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environmental and Molecular Mutagenesis, 19, 2–141.

Zimmermann FK and Mohr A, 1992. Formaldehyde, glyoxal, urethane, methyl carbamate, 2,3-butanedione, 2,3-hexanedione, ethyl acrylate, dibromoacetonitrile, 2-hydroxypropionitrile induce chromosome loss in saccharomyces cerevisiae. Mutation Research, 270, 151–166.

Abbreviations

APET added portions exposure technique
bw body weight
CA chromosomal aberrations
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHL Chinese hamster lung (cells)
CHO Chinese hamster ovary (cells)
CoE Council of Europe
FAO Food and Agriculture Organization of the United Nations
FCM food contact materials
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GSH glutathione
IARC International Agency for Research on Cancer
ID Identity
IR infrared spectroscopy
i.p. intraperitoneal
JECCA The Joint FAO/WHO Expert Committee on Food Additives
MN micronuclei
MSDI Maximised Survey-derived Daily Intake
NCE normochromatic erythrocyte
NOAEL no observed adverse effect level
NPSH non-protein sulfhydryl
NTP National Toxicology Program
OECD Organisation for Economic Cooperation and Development
| Acronym | Description |
|---------|-------------|
| PCE     | polychromatic erythrocytes |
| SCE     | sister chromatid exchanges |
| SCF     | Scientific Committee on Food |
| SML     | specific migration limit |
| SPET    | single portion exposure technique |
| TDI     | tolerable daily intake |
| WHO     | World Health Organization |
## Appendix A – Genotoxicity data evaluated in FGE.71

### Table A.1: Genotoxicity data on ethyl acrylate [FL-no: 09.037] evaluated by JECFA (2006) and considered by EFSA in FGE.71 (2010)

| Chemical name | End-point | Test system | Concentration | Results | Reference | Comments |
|---------------|-----------|-------------|---------------|---------|-----------|----------|
| Ethyl acrylate 09.037 | Reverse mutation | *Salmonella* Typhimurium TA98, TA100, TA1535, TA1537 and TA1538 | 30–2,000 μg/plate | Negative<sup>(a)</sup> | Waegemaekers and Bensink (1984) | Reliable with the following restriction: the study complied with current recommendations with the exception that tester strains TA102 or *E. coli* WP2uvrA were not used |
| | | *S. Typhimurium* TA97, TA98, TA100 and TA1535 | 33–3,333 μg/plate | Negative<sup>(a),(b)</sup> | Zeiger et al. (1992) | Reliable with the following restriction: the study complied with current recommendations with the exception that tester strains TA102 or *E. coli* WP2uvrA were not used |
| | | *S. Typhimurium* TA98, TA100, TA1535 and TA1537 | 100–10,000 μg/plate | Equivocal<sup>(a),(b),(c)</sup> | Haworth et al. (1983) | Reliable with the following restriction: the study complied with current recommendations with the exception that tester strains TA102 or *E. coli* WP2uvrA were not used |
| | | *S. Typhimurium* TA98, TA100 and TA1537 | NR | Negative<sup>(a),(b)</sup> | Ishidate et al. (1981) | No data reported |
| | | *S. Typhimurium* | ≤ 10,000 μg/plate | Negative<sup>(a)</sup> | Tennant et al. (1987) | Reliable with restrictions (review paper without detailed results) |
| | Mitotic chromosomal recombination | *Saccharomyces cerevisiae* D61.M | ≤ 1,095 μg/mL | Negative<sup>(d),(e)</sup> | Zimmermann and Mohr (1992) | Reliable. Endpoint of low relevance, no OECD guideline available |
| | | *S. cerevisiae* D61.M | ≤ 1,095 μg/mL | Positive<sup>(d)</sup> | | |
| | | *S. cerevisiae* D61.M | ≤ 914 μg/mL | Negative<sup>(e)</sup> | | |
| | Forward mutation | Mouse lymphoma L5178Y Tk<sup>–/–</sup> cells | 20 μg/mL | Positive<sup>(f)</sup> | Tennant et al. (1987) | Reliable with restrictions (review paper without detailed results) |
| | | Mouse lymphoma L5178Y Tk<sup>–/–</sup> cells | 10, 15, 20, 25, 27.5, 30, 32.5, 35, 40 or 50 μg/mL | Positive<sup>(f),(g)</sup> | Ciaccio et al. (1998) | Reliable without restrictions. Study in line with OECD guideline No. 490 |
| Chemical name | End-point | Test system | Concentration | Results | Reference | Comments |
|---------------|-----------|-------------|---------------|---------|-----------|----------|
| FL-no | JECFA-no |
| | Mouse lymphoma L5178Y Tk-/- cells | 20, 25, 30 or 37.5 µg/mL | Positive(f),(h) | Moore et al. (1988) | Reliable without restrictions. Study in line with OECD guideline No. 490 Large majority of mutants are small-colony mutants |
| | Mouse lymphoma L5178Y Tk-/- cells | 2.5-40 µg/mL | Positive(f),(i) | McGregor et al. (1988) | Reliable without restrictions. Study in line with OECD guideline No. 490 Positive only at highest dose. Equivocal using the ‘global evaluation factor approach’ |
| | Chinese hamster ovary cells | 299 µg/mL ≤ 29.9 µg/mL | Positive(i) Negative(f),(h) | Loveday et al. (1990) | Reliable without restrictions Study in line with OECD guideline No. 473 |
| | Mouse lymphoma L5178Y Tk-/- cells | 20, 25, 30 or 37.5 µg/mL | Positive(f),(h) | Moore et al. (1988) | Reliable without restrictions Study in line with OECD guideline No. 473 |
| | Chinese hamster lung cells | 0.0098 mg/mL (9.8 µg/mL) | Positive(a) | Ishidate et al. (1981) | Reliable with restrictions (review paper without detailed results) |
| | Chinese hamster ovary cells | 299 µg/mL | Positive(i) Negative(f) | Tennant et al. (1987) | Reliable with restrictions (review paper without detailed results) |
| | Chinese hamster ovary cells | 150 µg/mL | Positive(i) Negative(f) | | Reliable with restrictions (review paper without detailed results) OECD guideline was withdrawn |
| | Chinese hamster ovary cells | 150 µg/mL ≤ 5 µg/mL | Weak positive(f) Negative(f),(h) | Loveday et al. (1990) | Reliable without restrictions. The endpoint has low relevance (OECD guideline was withdrawn) |
| | Mouse lymphoma L5178Y Tk-/- cells | 20.0-37.5 µg/mL | Positive(f),(h) | Moore et al. (1988) | Reliable without restrictions. The endpoint has low relevance (OECD guideline was withdrawn) |
| | Mouse splenocytes | 10-80 µg/mL | Negative(l) | Kligerman et al. (1991) | Reliable without restrictions. The endpoint has low relevance (OECD guideline was withdrawn) |
| Chemical name     | End-point                  | Test system                        | Concentration                  | Results     | Reference                        | Comments                                                                 |
|-------------------|----------------------------|------------------------------------|-------------------------------|-------------|----------------------------------|--------------------------------------------------------------------------|
| Ethyl acrylate    | Sister chromatid exchange | Male C57BL/6 mice                  | 125, 250, 500 or 1,000 mg/kg  | Negative    | Kligerman et al. (1991)          | *In vivo-vitro* study (animals were exposed, splenocytes were isolated and cultured *in vitro* (OECD guideline was withdrawn) |
|                   |                            |                                    |                               |             |                                  |                                                                          |
|                   | Chromosomal aberration     | Male C57BL/6 mice                  | 125, 250, 500 or 1,000 mg/kg  | Negative    |                                  |                                                                          |
|                   |                            |                                    |                               |             |                                  |                                                                          |
|                   | Micronucleus formation     | Male C57BL/6 mice                  | 125, 250, 500 or 1,000 mg/kg  | Negative(q) | Kligerman et al. (1991)          | *In vivo-vitro* study (animals were exposed, splenocytes were isolated and cultured *in vitro* This experimental protocol is not described in OECD guideline No. 475 |
|                   |                            | Male BALB/c mice                   | 225-1,800 mg/kg               | Positive    | Przybojewska et al. (1984)       | Reliable with restrictions: 4 animals/group were treated. Highest dose (1,800 mg/kg) was toxic. 2/4 animals died |
|                   |                            | Male and female C57BL/6 mice       | 461(n),(s) or 738 mg/kg       | Negative    | Ashby et al. (1989)              | Reliable with restrictions (review paper)                               |
|                   |                            | Male BALB/c mice                   | 812 mg/kg                    | Negative    |                                  |                                                                          |
|                   |                            | Male C57BL/6 mice                  | 738 mg/kg                    | Negative    |                                  |                                                                          |
|                   |                            | Male BDF1 mice                     | 188, 375 or 750 mg/kg        | Negative    | Hara et al. (1994)               | Reliable with restrictions (poor reporting)                               |
|                   |                            |                                    | 188, 375 or 750 mg/kg        | Negative(x) |                                  |                                                                          |
|                   |                            |                                    | 375, 500 or 750 mg/kg        | Negative(x) |                                  |                                                                          |
|                   |                            | Male BDF1 mice                     | 188, 375, 750 or 1,000 mg/kg | Negative(y) | Morita et al. (1997)             | Reliable with restrictions Basically following the OECD guidelines. Except that no data were reported on PCE/NCE ratio |
|                   |                            |                                    |                               |             |                                  |                                                                          |
| Chemical name          | End-point                      | Test system                          | Concentration | Results | Reference                        | Comments                                                                 |
|-----------------------|--------------------------------|--------------------------------------|---------------|---------|----------------------------------|--------------------------------------------------------------------------|
| FL-no JECFA-no         |                                |                                      |               |         |                                  |                                                                          |
| DNA alkaline elution   | Male F344 rat forestomach squamous epithelium | 0.1-4.0% (50-2,000 mg/kg)\(^{(v)}\) | Negative      | Morimoto et al. (1990) | Reliable without restrictions. No OECD guidelines are available     |
| Sex-linked recessive lethal mutations | Drosophila melanogaster | 20,000 mg/kg                        | Negative\(^{(o)}\)  | Valencia et al. (1985) | Reliable without restrictions. Low relevance of target organism. OECD guideline withdrawn |
| Micronucleus formation | D. melanogaster                | 18,000; 20,000 or 40,000 mg/kg      | Negative\(^{(p)}\)  | Valencia et al. (1985) | Reliable without restrictions. Low relevance of target organism. No OECD guideline available |

OECD: Organisation for Economic Cooperation and Development; PCE: polychromatic erythrocyte; NCE: normochromatic erythrocyte.

\(\text{(a)}\): With and without metabolic activation.
\(\text{(b)}\): Pre-incubation method.
\(\text{(c)}\): The Ames tests were performed by two different laboratories, resulting in positive and negative results in the first and second experiments, respectively. The authors considered the results from the confirmation (second) experiment to be more definitive.
\(\text{(d)}\): Cold shock regimen (i.e. 4-h incubation at 28°C, followed by a 16-h storage in an ice bath and a 4-h incubation at 28°C).
\(\text{(e)}\): Uninterrupted 16-h incubation at 28°C.
\(\text{(f)}\): Without metabolic activation.
\(\text{(g)}\): Relative cell growth was 20% and 13%, respectively, at the two highest doses tested (40 and 50 μg/mL, respectively).
\(\text{(h)}\): Cytotoxicity was observed at the highest dose tested.
\(\text{(i)}\): Statistically significant increases in mutant fraction were observed at doses of 20 and 40 μg/mL.
\(\text{(j)}\): With metabolic activation.
\(\text{(k)}\): Dose at which chromosomal aberrations were detected in 20% of metaphase cells.
\(\text{(l)}\): Exposure during the G0 phase of the cell cycle. Cytotoxicity was observed at doses of >30 μg/mL.
\(\text{(m)}\): Exposure during the G-S phase of the cell cycle. Cytotoxicity was observed at doses of >10 μg/mL.
\(\text{(n)}\): Administered intraperitoneally.
\(\text{(o)}\): Injection experiment.
\(\text{(p)}\): Feeding experiment.
\(\text{(q)}\): A slight but significant increase in the frequency of micronucleus formation was observed at the highest dose tested (1000 mg/kg), which was thought to be due to an elevated frequency in one of the four treated mice.
\(\text{(r)}\): Administered intraperitoneally in two doses within 24 h.
\(\text{(s)}\): Assessment of bone marrow for formation of micronuclei 24 h after dosing.
\(\text{(t)}\): Assessment of bone marrow for formation of micronuclei 48 or 72 h after dosing.
\(\text{(u)}\): Administered intraperitoneally at 0 and 24 h, followed by assessment of bone marrow for formation of micronuclei 6 h later.
\(\text{(v)}\): Administered orally.
\(\text{(w)}\): Administered orally twice within 24-h.
\(\text{(x)}\): A significant decrease in the reticulocyte ratio was observed at the highest dose tested compared with vehicle controls.
\(\text{(y)}\): Mortality was observed at the highest dose tested (1,000 mg/kg).
### Appendix B – Previously not considered genotoxicity data

#### Table B.1: *In vitro* genotoxicity studies on ethyl acrylate [FL-no: 09.037]

| Chemical name              | End-point | Test system                                      | Concentration | Results | Reference               | Comments                                                                 |
|----------------------------|-----------|--------------------------------------------------|---------------|---------|-------------------------|--------------------------------------------------------------------------|
| Ethyl acrylate 09.037 1351 | Ames test | *Salmonella* Typhimurium TA102                    | Up to 5,000 μg/plate | Negative | Kirkland et al. (2016)  | Reliable without restrictions. The study complies with OECD Test Guideline 471 |
|                           |           | *S. Typhimurium* strain YG7108, transformed with the plasmid pin3ERb5 | Up to 2,000 μg/plate | Negative | Emmert et al. (2006)    | Reliable without restrictions. The study was designed to test the compound in a metabolically competent *S. Typhimurium* strain |
|                           | Micronucleus Assay | p53-deficient rodent cell lines: V79 | 0–20^{(b),(c)}; 0–8^{(b),(d)} μg/mL | Positive^{(b),(c),(d)} | Fowler et al. (2012a) | Reliable without restrictions. In the short-term treatment, MN were induced at concentrations of ethyl acrylate resulting in cytotoxicity of 50–60% The study was designed to investigate the different results in the MN assay depending on the cell line |
|                           |           | CHO                                              | 0–32^{(b),(c)}; 0–12^{(b),(d)} μg/mL | Positive^{(b),(c)}; Negative^{(b),(d)} |                       |                                                                          |
|                           |           | CHL                                              | 0–40^{(b),(c)}; 0–14^{(b),(d)} μg/mL | Positive^{(b),(c)} and (b),(d) |                       |                                                                          |
|                           |           | p53-competent human cells: peripheral blood lymphocytes | 0–50^{(b),(c)}; 0–10.4^{(b),(d)} μg/mL | Positive^{(b),(c)}; Negative^{(b),(d)} |                       |                                                                          |
|                           |           | TK6 human lymphoblastoid cells                   | 0–28^{(b),(c)}; 0–12^{(b),(d)} μg/mL | Positive^{(b),(c)}; Negative^{(b),(d)} |                       |                                                                          |
|                           |           | HepG2                                            | 0–9^{(b),(c)}; 0–15^{(b),(d)} μg/mL | Equivocal^{(b),(c)}; Negative^{(b),(d)} |                       |                                                                          |
|                           |           | p53-mutant mouse lymphoma L5178Y                 | 0–18 μg/mL | Equivocal in the absence of cytochalasin B | Whitwell et al. (2015) | Reliable without restrictions. The study was designed to investigate the possible role of p53 and apoptosis in the micronuclei induction |
|                           |           | p53-competent human lymphoblastoid TK6           | 0–10 μg/mL | Equivocal with both human cell lines in the presence of cytochalasin B |                       |                                                                          |
| Chemical name | End-point | Test system                  | Concentration | Results                                           | Reference | Comments |
|---------------|-----------|------------------------------|---------------|--------------------------------------------------|-----------|----------|
|               |           | p53-mutant human WIL2-NS cells | 0–9 μg/mL     | Negative with both human cell lines in the absence of cytochalasin B |           |          |

OECD: Organisation for Economic Cooperation and Development.
(a): With metabolic activation.
(b): Without metabolic activation.
(c): 3 h treatment + 21 h recovery.
(d): 24 h treatment + 0 h recovery.
Appendix C – Exposure

Calculation of the Dietary Exposure - APET

Chronic Dietary Exposure – ‘Added Portions Exposure Technique’ (APET)

The chronic APET calculations are based on the normal combined occurrence level by adding the highest contributing portion of food and highest contributing portion of beverages (either among soft drinks or alcoholic beverages). APET for children is calculated by adding the highest contributing portion of food and highest contributing portion of beverages (among soft drinks). Furthermore, in the APET calculation for children, the portion sizes listed in Table 8 is adjusted by a factor 0.63 to take into account the smaller portion sizes consumed by the child.

Adults (‘Added Portions Exposure Technique’ [APET])

On the basis of normal occurrence level from the added flavouring only

Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 µg/adult per day.

Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 µg/adult per day.

The total APET will be 3,545 µg/adult per day corresponding to 59.1 µg/kg bw per day for a 60-kg person.

Children (3-year-old child of 15 kg body weight)

Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 x 0.63 = 1,335 µg/child per day.

Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 x 0.63 = 898 µg/child per day.

The total APET will be 2,233 µg/child per day corresponding to 149 µg/kg bw per day for a 15-kg child.

Conclusion

The higher of the two values among adults and children, expressed per kg/bw per day, should be used as the basis for the safety evaluation of the candidate substance, i.e. the value of 150 µg/kg bw per day for a 15-kg child should be compared to the appropriate no observed adverse effect level (NOAEL) for the candidate substance.

Combined Dietary Exposure

This is an estimate of total dietary exposure deriving from both the addition of the flavouring substance to foods and beverages and other dietary sources. To estimate the APET for combined dietary exposure, the occurrence of the substance in grapes and vanilla was also taken into account in the estimation.

Adults (‘Added Portions Exposure Technique’ [APET])

Solid Food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 µg/adult per day.

Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of 1,425 µg/adult per day.

The total APET will be 3,545 µg/adult per day corresponding to 59.1 µg/kg bw per day for a 60-kg person.

Children (3-year-old child of 15 kg body weight)

Solid food: The maximum intake will be from category 1.0 (Dairy products) with the normal combined occurrence level of 2,120 x 0.63 = 1,335 µg/child per day.

---

5 The APET has been calculated based on the occurrence levels in the food subcategories reported in the above table, with the exclusion of categories 13.2 (complementary foods for infants and young children).
Beverage: The category 14.1 (Non-alcoholic (‘soft’) beverages, excl. dairy products) to which the candidate substance is added have the same normal combined occurrence level of $1,425 \times 0.63 = 898 \mu g/\text{child per day}$.

The total APET will be $2,233 \mu g/\text{child per day}$ corresponding to $149 \mu g/\text{kg bw per day}$ for a 15-kg child.
| Food categories<sup>(a)</sup> | Standard portions<sup>(b) (g)</sup> | Occurrence level as added flavouring substance (mg/kg) | Occurrence level from other sources<sup>(c) (mg/kg)</sup> | Combined occurrence level from all sources<sup>(d) (mg/kg)</sup> |
|-----------------------------|----------------------------------|-------------------------------------------------|------------------------------------------------|----------------------------------|
|                             | Normal                           | Maximum                                        | Average<sup>(d) d</sup> | Maximum |
| 01.1 Milk and dairy-based drinks | 200                              | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.2 Fermented and renneted milk products (plain), excluding food category 01.1.2 (dairy-based drinks) | 200                              | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.3 Condensed milk and analogues (plain) | 70                               | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.4 Cream (plain) and the like | 15                               | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.5 Milk powder and cream powder and powder analogues (plain) | 30                               | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.6 Cheese and analogues | 40                               | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.7 Dairy-based desserts (e.g. pudding, fruit or flavoured yoghurt) | 125                              | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 01.8 Whey and whey products, excluding whey cheeses | 200                              | 10.6                                           | 15.2                                           | 10.6                                           | 15.2                                           |
| 02.1 Fats and oils essentially free from water | 15                               |                                                 |                                                 |                                                 |                                                 |
| 02.2 Fat emulsions mainly of type water-in-oil | 15                               |                                                 |                                                 |                                                 |                                                 |
| 02.3 Fat emulsions mainly of type water-in-oil, including mixed and/or flavoured products based on fat emulsions | 15                               |                                                 |                                                 |                                                 |                                                 |
| 02.4 Fat-based desserts excluding dairy-based dessert products of category 1.7 | 50                               |                                                 |                                                 |                                                 |                                                 |
| 03.0 Edible ices, including sherbet and sorbet | 50                               |                                                 |                                                 |                                                 |                                                 |
| 04.1.1 Fresh fruit | 140                              | 0.1                                             | 0.1                                             | 0.1                                             | 0.1                                             |
| 04.1.2 Processed fruit | 125                              | 0.1                                             | 0.1                                             | 0.1                                             | 0.1                                             |
| 04.1.2.5 Jams, jellies, marmalades | 30                               |                                                 |                                                 |                                                 |                                                 |
| 04.2.1 Fresh vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe vera), seaweed, and nut and seed | 200                              |                                                 |                                                 |                                                 |                                                 |
| 04.2.2 Processed vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe vera), seaweed, and nut and seed purees and spreads (e.g. peanut butter) and nuts and seeds | 200                              |                                                 |                                                 |                                                 |                                                 |
| 04.2.2.5 Vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes, and aloe vera), seaweed, and nut and seed purees and spreads (e.g. peanut butter) | 30                               |                                                 |                                                 |                                                 |                                                 |
| 05.1 Cocoa products and chocolate products, including imitations and chocolate substitutes | 40                               | 10.14                                          | 13.3                                           | 10.14                                          | 13.3                                           |
| Food categories<sup>(a)</sup> | Standard portions<sup>(b)</sup> (g) | Occurrence level as added flavouring substance (mg/kg) | Occurrence level from other sources<sup>(c)</sup> (mg/kg) | Combined occurrence level from all sources<sup>(d)</sup> (mg/kg) |
|-------------------------------|----------------------------------|-----------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                              | Normal                           | Maximum                                             | Average<sup>(d)</sup> | Maximum                          |
| 05.1.3 Cocoa-based spreads, including fillings | 30 | 10.14 | 13.3 | 10.14 | 13.3 |
| 05.2 Confectionery, including hard and soft candy, nougats, etc., other than 05.1, 05.3 and 05.4 | 30 | 10.14 | 13.3 | 10.14 | 13.3 |
| 05.3 Chewing gum | 3 | 0.07 | 0.11 | 0.07 | 0.11 |
| 05.4 Decorations (e.g. for fine bakery wares), toppings (non-fruit) and sweet sauces | 35 | 10.14 | 13.3 | 10.14 | 13.3 |
| 06.1 Whole, broken or flaked grain, including rice | 200 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.2 Flours and starches (including soya bean powder) | 30 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.3 Breakfast cereals, including rolled oats | 30 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.4 Pastas and noodles and like products (e.g. rice paper, rice vermicelli, soya bean pastas and noodles) | 200 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.5 Cereal- and starch-based desserts (e.g. rice pudding, tapioca pudding) | 200 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.6 Batters (e.g. for breading or batters for fish or poultry) | 30 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.7 Pre-cooked or processed rice products, including rice cakes (Oriental type only) | 200 | 6.77 | 10.84 | 6.77 | 10.84 |
| 06.8 Soya bean products (excluding soya bean products of food category 12.9 and fermented soya bean products of food category 12.10) | 100 | 6.77 | 10.84 | 6.77 | 10.84 |
| 07.1 Bread and ordinary bakery wares | 50 | 11.75 | 13.76 | 11.75 | 13.76 |
| 07.2 Fine bakery wares (sweet, salty, savoury) and mixes | 80 | 11.75 | 13.76 | 11.75 | 13.76 |
| 08.1 Fresh meat, poultry and game | 200 | 0.1 | 0.1 | 0.1 | 0.1 |
| 08.2 Processed meat, poultry and game products in whole pieces or cuts | 100 | 0.1 | 0.1 | 0.1 | 0.1 |
| 08.3 Processed comminute meat, poultry and game products | 100 | 0.1 | 0.1 | 0.1 | 0.1 |
| 08.4 Edible casings (e.g. sausage casings) | 1 | 0.1 | 0.1 | 0.1 | 0.1 |
| 09.1.1 Fresh fish | 200 | | | |
| 09.1.2 Fresh molluscs, crustaceans and echinoderms | 200 | | | |
| 09.2 Processed fish and fish products, including molluscs, crustaceans and echinoderms | 100 | | | |
| Food categories<sup>(a)</sup> | Standard portions<sup>(b)</sup> (g) | Occurrence level as added flavouring substance (mg/kg) | Occurrence level from other sources<sup>(c)</sup> (mg/kg) | Combined occurrence level from all sources<sup>(d)</sup> (mg/kg) |
|-------------------------------|-------------------------------------|-----------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                              |                                     | Normal | Maximum | Average<sup>(d)</sup> | Maximum | Normal | Maximum |
| 09.3 Semi-preserved fish and fish products, including molluscs, crustaceans and echinoderms | 100 | | | | | |
| 09.4 Fully preserved, including canned or fermented, fish and fish products, including molluscs, crustaceans and echinoderms | 100 | | | | | |
| 10.1 Fresh eggs | 100 | | | | | |
| 10.2 Egg products | 100 | | | | | |
| 10.3 Preserved eggs, including alkaline. salted and canned eggs | 100 | | | | | |
| 10.4 Egg-based desserts (e.g. custard) | 125 | | | | | |
| 11.1 Refined and raw sugar | 10 | | | | | |
| 11.2 Brown sugar excluding products of food category 11.1 | 10 | | | | | |
| 11.3 Sugar solutions and syrups, and (partially) inverted sugars, including molasses and treacle, excluding products of food category 11.1.3 (soft white sugar, soft brown sugar, glucose syrup, dried glucose syrup, raw cane sugar) | 30 | | | | | |
| 11.4 Other sugars and syrups (e.g. xylose, maple syrup, sugar toppings) | 30 | | | | | |
| 11.5 Honey | 15 | | | | | |
| 11.6 Table-top sweeteners, including those containing high-intensity sweeteners | 1 | | | | | |
| 12.1 Salt and salt substitutes | 1 | | | | | |
| 12.10 Protein products other than from soybeans | 15 | | | | | |
| 12.2 Herbs, spices, seasonings and condiments (e.g. seasoning for instant noodles) | 1 | | | | | |
| 12.3 Vinegars | 15 | | | | | |
| 12.4 Mustards | 15 | | | | | |
| 12.5 Soups and broths | 200 | | | | | |
| 12.6 Sauces and like products | 30 | | | | | |
| 12.7.a Salads 120 g (e.g. macaroni salad, potato salad) excluding cocoa- and nut-based spreads of food categories | 120 | | | | | |
| 12.7.b Sandwich spreads (20 g), excluding cocoa- and nut-based spreads of food categories | 20 | | | | | |
### Food categories

| Food categories                                      | Standard portions\(^{(b)}\) (g) | Occurrence level as added flavouring substance (mg/kg) | Occurrence level from other sources\(^{(c)}\) (mg/kg) | Combined occurrence level from all sources\(^{(d)}\) (mg/kg) |
|------------------------------------------------------|---------------------------------|--------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------------------|
| 12.8  Yeast and like products                        |                                 | Normal (mg/kg) | Maximum (mg/kg) | Average\(^{(d)}\) (mg/kg) | Maximum (mg/kg) |
| 12.9  Soybean-based seasonings and condiments        |                                 | 15            | 15            | 15                          | 15            |
| 12.9.1 Fermented soya bean products (e.g. miso)      |                                 | 40            | 40            | 40                          | 40            |
| 12.9.2 Soybean sauce                                 |                                 | 15            | 15            | 15                          | 15            |
| 12.9.3 Fermented soybean sauce                       |                                 | 15            | 15            | 15                          | 15            |
| 13.2.a Complementary foods for infants and young children: Dry instant cereals (with or without milk), including pasta | 110                              |               |               |                              |               |
| 13.2.b Complementary foods for infants and young children: Meat-based or fish-based dinner | 170                              |               |               |                              |               |
| 13.2.c Complementary foods for infants and young children: Dairy-based dessert | 110                              |               |               |                              |               |
| 13.2.d Complementary foods for infants and young children: Vegetables, potatoes, broth, soups, pulses | 170                              |               |               |                              |               |
| 13.2.e Complementary foods for infants and young children: Biscuits and cookies | 20                                |               |               |                              |               |
| 13.2.f Complementary foods for infants and young children: Fruit purée | 110                              |               |               |                              |               |
| 13.2.g Complementary foods for infants and young children: Fruit juice | 120                              |               |               |                              |               |
| 13.2.h Milk for young children                       |                                 | 200           |               |                              |               |
| 13.3 Dietetic foods intended for special medical purposes (excluding food products of category 13.1 `Infant formulae, follow-up formulae and other formulae for special medical purposes for infants`) | 200                              |               |               |                              |               |
| 13.4 Dietetic formulae for slimming purposes and weight reduction | 200                              |               |               |                              |               |
| 13.5 Dietetic foods (e.g. supplementary foods for dietary use), excluding products of food categories 13.1 (Infant formulae, follow-up formulae and other formulae for special medical purposes for infants), 13.2–13.4 and 13.6 | 200                              |               |               |                              |               |
| 13.6 Food supplements                                |                                 | 5             |               |                              |               |
| 14.1 Other non-alcoholic ("soft") beverages (expressed as liquid) | 300                              | 4.75          | 8.75          | 4.75                        | 8.75          |
| 14.2.1 Beer and malt beverages                      |                                 | 300           | 0.38          | 1                           | 0.38          |
| 14.2.2 Cider and perry                              |                                 | 300           | 0.38          | 1                           | 0.38          |
### Food categories

| Food categories\(^{(a)}\) | Standard portions\(^{(b)}\) (g) | Occurrence level as added flavouring substance (mg/kg) | Occurrence level from other sources\(^{(c)}\) (mg/kg) | Combined occurrence level from all sources\(^{(e)}\) (mg/kg) |
|---------------------------|---------------------------------|------------------------------------------------------|---------------------------------------------------|------------------------------------------------------|
|                           |                                 | Normal | Maximum | Average\(^{(d)}\) | Maximum | Normal | Maximum |
| 14.2.3 Grape wines        | 150                             | 0.38   | 1       | 0.38               | 1       | 0.38   | 1       |
| 14.2.4 Wines (other than grape) | 150                             | 0.38   | 1       | 0.38               | 1       | 0.38   | 1       |
| 14.2.5 Mead               | 150                             | 0.38   | 1       | 0.38               | 1       | 0.38   | 1       |
| 14.2.6 Distilled spirituous beverages containing more than 15% alcohol | 30                              | 0.38   | 1       | 0.38               | 1       | 0.38   | 1       |
| 14.2.7 Aromatised alcoholic beverages (e.g. beer, wine and spirituous cooler-type beverages, low alcoholic refreshers) | 300                             | 0.38   | 1       | 0.38               | 1       | 0.38   | 1       |
| 15.1 Snacks, potato-, cereal-, flour- or starch-based (from roots and tubers, pulses and legumes) | 30                              |        |         |                    |         |        |         |
| 15.2 Processed nuts, including coated nuts and nut mixtures (with e.g. dried fruit) | 30                              |        |         |                    |         |        |         |
| 15.3 Snacks – fish-based  | 30                              |        |         |                    |         |        |         |
| 16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods that could not be placed in categories 01-15 | 300                             |        |         |                    |         |        |         |

\(^{(a)}\): Most of the categories reported are the sub-categories of Codex GSFA (General Standard for Food Additives, available at [http://www.codexalimentarius.net/gsfaoonline/CXS_192e.pdf](http://www.codexalimentarius.net/gsfaoonline/CXS_192e.pdf)), used by the JECFA in the SPET technique (FAO/WHO, 2008). In the case of category 13.2 (complementary foods for infants and young children), further refined categories have been created so that a specific assessment of dietary exposure can be performed in young children.

\(^{(b)}\): For Adults. In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the instructions reported on the product label or one of the standard dilution factors established by the JECFA (FAO/WHO, 2008):
- 1/25 for powder used to prepare water-based drinks such as coffee, containing no additional ingredients,
- 1/10 for powder used to prepare water-based drinks containing additional ingredients such as sugars (ice tea, squashes, etc.),
- 1/7 for powder used to prepare milk, soups and puddings,
- 1/3 for condensed milk.

\(^{(c)}\): As natural constituent and/or developed during the processing and/or as carry over resulting from their use in animal feed.

\(^{(d)}\): In order to estimate normal values in each category, only foods and beverages in which the substance is present in significant amount will be considered (e.g. for the category ‘Fresh fruit’ 04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where the flavouring substance is known to occur).

\(^{(e)}\): As added flavouring or from other sources. The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels from added use to that from other sources or by expert judgement based on the likelihood of their concomitant presence. This will be done both for normal use levels and for maximum use levels.